Belite Bio (BLTE) Q1 2026 earnings summary

Executive summary

• Initiated rolling NDA submission to FDA for tinlarebant in Stargardt disease (STGD1), expected to complete by Q2 2026, with commercialization preparation underway and all key commercial leadership positions filled.

• Completed enrollment in pivotal Phase 3 DRAGON II trial for STGD1, supporting Japan regulatory submission; PHOENIX trial for geographic atrophy (GA) also completed enrollment.

• Focus remains on U.S. FDA approval, with ex-U.S. filings to follow based on FDA outcome; Japan approval expected within three months of FDA decision due to Sakigake designation.

• Tinlarebant granted multiple regulatory designations, including Orphan Drug Status in Switzerland and Breakthrough Therapy in several regions.

Financial highlights

• Q1 2026 R&D expenses were $19.5M (GAAP), up from $8.8M in Q1 2025; SG&A expenses were $17.0M, up from $6.1M, driven by clinical and pre-commercial activities.

• Total operating expenses (GAAP) rose to $32.7M in Q1 2026 from $15.5M in Q1 2025.

• GAAP net loss for Q1 2026 was $26.9M versus $14.3M in Q1 2025; non-GAAP net loss (excluding share-based comp) was $13.7M versus $7.6M.

• Ended Q1 2026 with $798.6M in cash, equivalents, and U.S. Treasury bills and notes.

• Other income rose to $5.7M from $1.2M, mainly due to higher interest income.

Outlook and guidance

• NDA submission for tinlarebant in STGD1 expected to complete in Q2 2026, with commercial launch preparations ongoing.

• Japan approval anticipated within three months of FDA approval; ex-U.S. filings to follow FDA outcome.

• Interim analysis for PHOENIX trial in GA expected by year-end 2026, with potential for study resizing based on data.

• Commercial launch budget for Stargardt in U.S. estimated at $300M; pipeline budget for next three years at $150M.